U.S. Global Health Assistance: FY2001-FY2019 Request (CRS Report for Congress)
Premium Purchase PDF for $24.95 (33 pages)
add to cart or
subscribe for unlimited access
Pro Premium subscribers have free access to our full library of CRS reports.
Subscribe today, or
request a demo to learn more.
Release Date |
Revised July 9, 2018 |
Report Number |
R43115 |
Report Type |
Report |
Authors |
Tiaji Salaam-Blyther |
Source Agency |
Congressional Research Service |
Older Revisions |
-
Premium Revised June 22, 2018 (33 pages, $24.95)
add
-
Premium Revised June 2, 2018 (33 pages, $24.95)
add
-
Premium Revised Oct. 6, 2017 (29 pages, $24.95)
add
-
Premium Revised Sept. 5, 2017 (28 pages, $24.95)
add
-
Premium Revised May 11, 2015 (29 pages, $24.95)
add
-
Premium Revised July 21, 2013 (37 pages, $24.95)
add
-
Premium June 21, 2013 (38 pages, $24.95)
add
|
Summary:
Congressional interest in and support for global health programs has remained strong for several
years. In FY2018, Congress provided $8.7 billion for global health programs through State,
Foreign Operations appropriations and $488.6 million through Labor, Health and Human
Services, and Education (Labor-HHS) appropriations. These funds are managed by several U.S.
agencies and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund)—a
multilateral organization aimed at combating the three diseases worldwide. Concern about
infectious diseases, especially HIV/AIDS, tuberculosis, and malaria (HTAM), continues to drive
budget growth. In FY2001, roughly 47% of the U.S. global health budget was aimed at these
three diseases. By FY2018, almost 75% of U.S. global health funding was provided for fighting
HTAM. The Appendix outlines U.S. funding for global health by agency and program. The 115
th
Congress may debate several pressing global health issues, including the following:
Strengthening Health Systems. The global spread of recent disease outbreaks,
including Ebola and Zika, has intensified debates about the advantages and
disadvantages of disease-specific funding. Congressional interest in bolstering
weak health systems was particularly strong during the Ebola outbreak.
Congressional discussions about health system strengthening have been waning,
though some interest remains, including in proposed legislation (see for example
H.Res. 342, 115th Congress).
Bolstering Pandemic Preparedness. Since 1980, infectious diseases have
caused outbreaks that have been occurring with greater frequency and have been
leading to higher numbers of human infections. Outbreaks caused by diseases
that were once concentrated in tropical regions, including Ebola and Zika, are
spreading through international travel. At the same time, long-standing diseases
like tuberculosis and malaria are becoming increasingly resistant to available
drugs and also threaten global health.
The United States has been a key supporter in global efforts to bolster pandemic
preparedness in low- and middle- income countries. It is unclear whether the 115th
Congress will sustain high levels of supports, including through funding, for global health
security efforts. In its report on H.R. 5515, National Defense Authorization Act for Fiscal
Year 2019, the House Committee on Armed Services directed the Secretary of Defense, in
coordination with the Assistant Secretary for Preparedness and Response at the
Department of Health and Human Services, to develop an action plan to counter
emerging infectious disease threats.
Considering the FY2019 Budget Request. The 115th Congress is considering
the FY2019 budget request, which includes over $7 billion for global health
assistance, roughly 24% less than FY2018 enacted levels. The Trump
Administration proposes reducing the USAID global health budget by nearly
40% through the elimination of funding for global health security, vulnerable
children, and HIV/AIDS programs and reductions to other health programs. The
Trump Administration also recommended cuts for PEPFAR programs managed
by the State Department (-11%), the Global Fund (-31%), and CDC global health
programs (-16%).
Protecting Life in Global Health Assistance. In 1984, former President Ronald
Reagan issued what has become known as the “Mexico City policy," which
required foreign nongovernmental organizations receiving USAID family
planning assistance to certify that they would not perform or actively promote
abortion as a method of family planning, even if such activities were conducted
with non-U.S. funds. The policy has been rescinded and reinstituted across
Administrations. Under the Trump Administration, the policy was reinstated,
renamed to Protecting Life in Global Health Assistance (PLGHA), and expanded
to apply to all global health programs.
Global health experts are working to measure the impact of the PLGHA policy.
Opponents maintain that the policy imperils all global health programs because some
health providers may not be able to disentangle FP/RH, HIV/AIDS, and maternal and
child health services from one another, particularly in areas with limited access to health
workers and facilities. Supporters maintain that although existing laws ban U.S. funds
from being used to perform or promote abortions abroad, money is fungible and the
PLGHA policy closes loopholes. Since the Mexico City Policy was first established,
Members on both sides of the issue have introduced legislation to permanently enact or
repeal the policy (for example, see H.R. 671 and S. 210, Global Health, Empowerment,
and Rights Act, 115th Congress).
Authorizing the extension of PEPFAR. Legislation that authorizes
appropriations for PEPFAR and describes congressional priorities for the
initiative expires September 30, 2018. PEPFAR continues to receive bipartisan
support and is being maintained by the Trump Administration, though at lower
levels than previous administrations. Following the release of the FY2018 budget
and Strategy, some HIV/AIDS advocates and Members of Congress questioned
the Administration’s commitment to controlling the global AIDS epidemic and
expressed concern about whether people on ART would lose coverage due to
spending cuts. The Administration has pledged to maintain the current level of
antiretroviral treatment provided through PEPFAR
Plans to maintain treatment levels are a departure from the Bush and Obama Administrations,
under which executive and legislative priorities for PEPFAR included steadily increasing the
number of people receiving ART through PEPFAR programs. Some Members of Congress have
challenged the Trump Administration’s approach to PEPFAR, raising questions about whether
executive and legislative consensus around broadening the reach of PEPFAR and advancing the
global goal of achieving an AIDS-free generation is fraying.